论文部分内容阅读
目的探讨盐酸法舒地尔联合依达拉奉治疗外伤性脑梗死(PTCI)的临床疗效。方法选取2013年7月—2014年11月南京医科大学第二附属医院收治的PTCI患者82例,随机分为观察组与对照组,各41例。对照组患者予以依达拉奉治疗,观察组患者在对照组基础上加用盐酸法舒地尔治疗。观察两组患者治疗前后格拉斯哥昏迷量表评分(GCS)、随访3个月后格拉斯哥预后量表评分(GOS)及不良反应发生情况。结果治疗前两组患者GCS评分比较,差异无统计学意义(P>0.05),治疗1、2个疗程后观察组患者GCS评分高于对照组,差异有统计学意义(P<0.05);观察组患者良好率高于对照组,中残率、重残率低于对照组,差异均有统计学意义(P<0.05),两组患者植物生存率及死亡率比较,差异无统计学意义(P>0.05);两组患者均未发生严重不良反应。结论盐酸法舒地尔联合依达拉奉治疗PTCI的临床疗效显著,可保护患者神经功能,且不良反应小。
Objective To investigate the clinical efficacy of fasudil combined with edaravone in the treatment of traumatic cerebral infarction (PTCI). Methods 82 patients with PTCI admitted to the Second Affiliated Hospital of Nanjing Medical University from July 2013 to November 2014 were randomly divided into observation group and control group, with 41 cases in each group. Patients in the control group were treated with edaravone. Patients in the observation group were treated with Fasudil Hydrochloride on the basis of the control group. The Glasgow Coma Scale (GCS) and the Glasgow Outcome Scale (GOS) and the incidence of adverse reactions after 3 months of follow-up were observed before and after treatment. Results There was no significant difference in GCS score between the two groups before treatment (P> 0.05). GCS score of observation group was higher than that of control group after treatment for 1 and 2 courses (P <0.05) The good rate of patients in the two groups was higher than that of the control group, and the rates of the morbidity and disability were lower than those in the control group (P <0.05). There was no significant difference in the survival rate and mortality between the two groups P> 0.05); no serious adverse reactions occurred in both groups. Conclusion The clinical efficacy of fasudil hydrochloride combined with edaravone in the treatment of PTCI is significant, which can protect the neurological function of patients with little adverse reaction.